Join Frank David and Ken Getz to discuss the practical factors that add risk to ...
"The patient community, all payers, all regulatory agencies, they all welcome mu...
The FDA is convening a meeting of outside experts today to consider full approva...
Updated results highlighted the ongoing benefits of a CRISPR-based medicine for ...
Follow our live blog of an FDA advisory panel's hearing on Leqembi, Eisai and Bi...
About 80% of large companies self-insure, meaning that their employee health pla...
The experts who scrutinized the manuscript for the journal before it was publish...
The fast track designation enables increased communication with the FDA througho...
KT430 delivers a functional copy of the MTM1 gene through a new MyoAAV capsid to...
The Prescription Cost Analysis also highlighted that the drug with the largest i...
The committee overwhelmingly supported nirsevimab’s risk-benefit profile in both...
VEVYE is a topical anti-inflammatory and immunomodulating ophthalmic drug solution.
Upstream Bio’s UPB-101 is currently being assessed in a Phase 1b trial to treat ...
The new 244,000ft² facility represents the company’s second significant expansio...
The vaccine has been developed by WestVac Biopharma along with the West China Me...
David McInerney, Cassie Commercial Manager, explains clinical data management ch...
